Equity Details
Price & Market Data
Price: $99.95
Daily Change: -$3.55 / 3.55%
Daily Range: $98.36 - $103.6
Market Cap: $6,427,921,408
Daily Volume: 645,694
Performance Metrics
1 Week: 0.75%
1 Month: 2.44%
3 Months: 19.16%
6 Months: 25.66%
1 Year: 120.8%
YTD: 14.44%
About Protagonist Therapeutics, Inc. (PTGX)
Find all you need to know about Protagonist Therapeutics, Inc. (PTGX)'s market performance. The stock is valued at 99.95, showing a daily change of -$3.55 / 3.55%. Its market capitalization is 6,427,921,408. Dive into its short-term and long-term performance trends.
Company Details
Employees: 132
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.